Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumors New candidate APVO455 targets Nectin-4+ cancers, joins ...
Octreotide scintigraphy versus DOTATOC PET: Concordance of Krenning scores and implications on PRRT treatment eligibility. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
-- First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort -- -- Management hosting webcast and conference call today at 1:30 p.m. ET / 10 ...
The FDA granted fast track designation (FTD) to IBI3003, a first-in-class trispecific antibody, for the treatment of patients ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ...
CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on ...
Hosted on MSN
Decoding the T cell burst: Signature genes predict T cell expansion in cancer immunotherapy
The ability of immune cells—particularly CD8 + T cells—to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results